"072. SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 104 WEEKS RESULTS FROM A PHASE 3 TRIAL" by Iain B. McInnes

Article

072. SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 104 WEEKS RESULTS FROM A PHASE 3 TRIAL

Rheumatology (2017)

Iain B. McInnes, University of Glasgow
Philip Mease, University of Washington
Christopher T. Ritchlin, University of Rochester
Proton Rahman, Memorial University of Newfoundland
Alice B. Gottlieb, New York Medical College
Bruce Kirkham, Guy's and St Thomas' NHS Foundation Trust

Link

Disciplines

Physical Therapy and
Medicine and Health Sciences

Publication Date

January 4, 2017

DOI

10.1093/rheumatology/kex062.072

Citation Information

Iain B. McInnes, Philip Mease, Christopher T. Ritchlin, Proton Rahman, et al.. "072. SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 104 WEEKS RESULTS FROM A PHASE 3 TRIAL" Rheumatology Vol. 56 (2017)
Available at: http://works.bepress.com/philip-mease/63/